Denali Therapeutics Inc.
NEWS
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2017.
Researchers at the University of California, San Diego (UCSD) ran successful animal studies of a gene therapy that appeared to cure a disease in mice similar to amyotrophic lateral sclerosis (ALS), sometimes also known as Lou Gehrig’s Disease.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
Shares of Denali Therapeutics are up more than 10 percent in premarket trading after the company announced it has inked a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases.
Denali Therapeutics stock climbed 11 percent after the release of positive data from its Phase I clinical trial of DNL201 in Parkinson’s disease.
In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
JOBS
IN THE PRESS